A type of anxiety marked by fear in some or all social settings (social anxiety disorder). Some early research shows that taking cannabidiol 300 mg daily does not improve anxiety during public speaking in people with social anxiety disorder. However, other early research in people with social anxiety disorder suggests that taking a higher dose (400-600 mg) may improve anxiety associated with public speaking or medical imaging testing. Also, some research in people who do not have social anxiety disorder shows that taking cannabidiol 300 mg might reduce anxiety during public speaking. cbd oil
The only proven to be good for you range of CBD products that support your health and general well-being. No other CBD product on the market can make these claims or even suggest that their products are good for your health and well-being. Each of our formulations is backed up by substantial scientific data. This has enabled us to present our products with these claims that have been certified and approved for use by the European Food Safety Authority. This really is the first and only well-being product on the market.
For epilepsy: A prescription cannabidiol product (Epidiolex) has been used. The recommended starting dose is usually 2.5 mg/kg twice daily (5 mg/kg/day). After one week the dose can be increased to 5 mg/kg twice daily (10 mg/kg/day). If the person doesn't respond to this dose, the maximum recommended is 10 mg/kg twice daily (20 mg/kg/day). In some research, higher doses of up to 50 mg/kg daily have been used. There is no strong scientific evidence that nonprescription cannabidiol products are beneficial for epilepsy.
^ Jump up to: a b c "FDA warns company marketing unapproved cannabidiol products with unsubstantiated claims to treat cancer, Alzheimer's disease, opioid withdrawal, pain and pet anxiety". US Food and Drug Administration. July 23, 2019. Retrieved July 24, 2019. Unlike drugs approved by the FDA, the manufacturing process of these products has not been subject to FDA review as part of the drug approval process, and there has been no FDA evaluation of whether these products are effective for their intended use, what the proper dosage is, how they could interact with FDA-approved drugs, or whether they have dangerous side effects or other safety concerns.
The endocannabinoid system is found in all mammals, and is made up of millions of cannabinoid receptor sites (CB1 and CB2 receptors) located throughout the body. The endocannabinoid system is one of the regulatory systems in the human body, but most people do very little to support the health of this system, because cannabinoids have not been part of the average diet. If you would like to know more about the technical aspects of the endocannabinoid system, you can go here. cbd oil

State and local governments may also regulate CBD. For example, the Massachusetts Department of Agricultural Resources issued a rule in June 2019 aligning state CBD regulations with FDA regulations. This means that although recreational marijuana is legal in the state, CDB cannot legally be sold in food or as a dietary supplement under state law.[89] cbd oil
^ Jump up to: a b c Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS (December 2012). "Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences (Review). 367 (1607): 3364–78. doi:10.1098/rstb.2011.0389. PMC 3481531. PMID 23108553.
In September 2018, following its approval by the FDA for rare types of childhood epilepsy,[12] Epidiolex was rescheduled (by the Drug Enforcement Administration) as a Schedule V drug to allow for its prescription use.[72] This allows GW Pharmaceuticals to sell Epidiolex, but it does not apply broadly and all other CBD-containing products remain Schedule I drugs.[72] Epidiolex still requires rescheduling in some states before it can be prescribed in those states.[75][76]

In addition, some cannabinoids interact synergistically, producing unique effects that are not found when using them individually. For example, CBD inhibits THC’s psychotropic effects when the two are taken together. However, CBD does this (and produces many other effects) without directly interacting with the cannabinoid receptors. At first, scientists thought there was a third type of CB receptor just for Cannabidiol, but the answer was far more interesting and revealing.

This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.


The oral bioavailability of CBD is 13 to 19%, while its bioavailability via inhalation is 11 to 45% (mean 31%).[4][5] The elimination half-life of CBD is 18–32 hours.[6] Cannabidiol is metabolized in the liver as well as in the intestines by CYP2C19 and CYP3A4 enzymes, and UGT1A7, UGT1A9, and UGT2B7 isoforms.[2] CBD may have a wide margin in dosing.[16]
Some preliminary research suggests that CBD may help with arthritis pain. In animal studies, which may not translate to humans, CBD relieved arthritis pain and inflammation. On the other hand, results of human studies are mixed. For example, a 2016 analysis of human trials for RA, OA and fibromyalgia found that CBD improved pain and sleep, but the studies were small and of poor quality.

The two main receptors in the endocannabinoid system are CB1 and CB2. Where THC directly affects these receptors, CBD has a subtler, more indirect approach. Instead of attaching to these receptors, CBD affects how these receptors signal the body and its chemicals. Furthermore, CBD increases the production of the body’s own cannabinoids by blocking the enzymes that can break them down.


Disclaimer: This product is not for use by or sale to persons under the age of 18. This product should be used only as directed on the label. It should not be used if you are pregnant or nursing. Consult with a physician before use if you have a serious medical condition or use prescription medications. A Doctor's advice should be sought before using this and any supplemental dietary product. All trademarks and copyrights are property of their respective owners and are not affiliated with nor do they endorse this product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. Individual weight loss results will vary. By using this site, you agree to follow the Privacy Policy and all Terms & Conditions printed on this site. Void Where Prohibited by Law.


Multiple sclerosis (MS). A prescription-only nasal spray product (Sativex, GW Pharmaceuticals) containing both 9-delta-tetrahydrocannabinol (THC) and cannabidiol has been shown to be effective for improving pain, muscle-tightness, and urination frequency in people with MS. This product is used in over 25 countries outside of the United States. But there is inconsistent evidence on the effectiveness of cannabidiol for symptoms of multiple sclerosis when it is used alone. Some early research suggests that using a cannabidiol spray under the tongue might improve pain and muscle tightness, but not muscle spasms, tiredness, bladder control, mobility, or well-being and quality of life in patients with MS.
Prescription medicine (Schedule 4) for therapeutic use containing 2 per cent (2.0%) or less of other cannabinoids commonly found in cannabis (such as ∆9-THC). A schedule 4 drug under the SUSMP is Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription.[57] cannabidiol oil
×